title: Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients.
abstract: The aim of this study is to assess the effects of sibutramine (S) 15 mg/day, fluoxetine (F) 60 mg/day, and metformin (M) 1,700 mg/day, as an adjunct therapy to a 1,500 kcal/day diet, in reducing anthropometric and metabolic parameters. S (n= 8), F (n= 9), and M (n= 8) were compared to placebo (n= 10) in 35 obese patients in a 90-day trial. Side effects were also studied during the treatment. The data demonstrated that F therapy resulted in a greater average reduction in BMI (11.0%), weight (10.0%), abdominal circumference (11.0%) and %fatty-tissue (12.8). An elevation in HDL-cholesterol (25.8%) and a reduction in average triglyceride levels (28.3%) were also shown. S presented a 7.91% reduction in the abdominal circumference and a 9.65 reduction in %fatty-tissue was also found. M group presented reductions in BMI (4.03%), waist circumference (6.92%), HOMA (23.5%) and blood pressure (6.08% in systolic and 2.08% in diastolic). In general, the three drugs can be considered well tolerated. We concluded that F and S demonstrated a greater mean reduction in anthropometric and metabolic parameters when compared to M, however all of them are useful for that purpose, when the subjects characteristics are considered.
authors.affiliation: Department of Clinical, Toxicological and Bromatological Analysis, Faculty of Pharmaceutical Sciences of Ribeirão Preto.
authors.forename: Camila
authors.initials: C
authors.lastname: Guimarães
authors.forename: Leonardo R L
authors.initials: LR
authors.lastname: Pereira
authors.forename: Nélson
authors.initials: N
authors.lastname: Iucif Júnior
authors.forename: Evandro José
authors.initials: EJ
authors.lastname: Cesarino
authors.forename: Carlos A N
authors.initials: CA
authors.lastname: de Almeida
authors.forename: Dermeval
authors.initials: D
authors.lastname: de Carvalho
authors.forename: Regina H C
authors.initials: RH
authors.lastname: Queiroz
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage* / Q000009:adverse effects; D001067:Appetite Depressants / Q000008:administration & dosage* / Q000009:adverse effects; D002784:Cholesterol / Q000009:adverse effects / Q000097:blood; D003131:Combined Modality Therapy; D003503:Cyclobutanes / Q000008:administration & dosage / Q000009:adverse effects; D005473:Fluoxetine / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy* / Q000378:metabolism; D010919:Placebos; D016037:Single-Blind Method
chemical_list: D018687:Antidepressive Agents, Second-Generation; D001067:Appetite Depressants; D003503:Cyclobutanes; D007004:Hypoglycemic Agents; D010919:Placebos; D005473:Fluoxetine; D008687:Metformin; D002784:Cholesterol; C058254:sibutramine